{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:02:46Z","timestamp":1792069366288,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Experimental Cancer Medicine Centre Pump-Priming Fund","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Wellcome-Health Research Board Irish Clinical Academic Training Programme","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The evaluation of circulating tumour DNA (ctDNA) from clinical blood samples, liquid biopsy, offers several diagnostic advantages compared with traditional tissue biopsy, such as shorter processing time, reduced patient risk and the opportunity to assess tumour heterogeneity. The historically poor sensitivity of ctDNA testing, has restricted its integration into routine clinical practice for non-metastatic disease. The early kinetics of ctDNA during radical radiotherapy for localised NSCLC have not been described with ultra-deep next generation sequencing previously.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Patients with CT\/PET-staged locally advanced, NSCLC prospectively consented to undergo serial venepuncture during the first week of radical radiotherapy alone. All patients received 55Gy in 20 fractions. Plasma samples were processed using the commercially available Roche AVENIO Expanded kit (Roche Sequencing Solutions, Pleasanton, CA, US) which targets 77 genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tumour-specific mutations were found in all patients (1 in 3 patients; 2 in 1 patient, and 3 in 1 patient). The variant allele frequency of these mutations ranged from 0.05\u20133.35%. In 2 patients there was a transient increase in ctDNA levels at the 72\u2009h timepoint compared to baseline. In all patients there was a non-significant decrease in ctDNA levels at the 7-day timepoint in comparison to baseline (<jats:italic>p<\/jats:italic>\u2009=\u20090.4627).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates the feasibility of applying ctDNA-optimised NGS protocols through specified time-points in a small homogenous cohort of patients with localised lung cancer treated with radiotherapy. Studies are required to assess ctDNA kinetics as a predictive biomarker in radiotherapy. Priming tumours for liquid biopsy using radiation warrants further exploration.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13014-020-01583-7","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T13:03:08Z","timestamp":1590757388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-9732","authenticated-orcid":false,"given":"G. M.","family":"Walls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"McAleese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. B.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gonzalez","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"1583_CR1","first-page":"163","volume-title":"Merlin J-L, von Bubnoff N, editors","author":"N Papadopoulos","year":"2020","unstructured":"Papadopoulos N. Pathophysiology of ctDNA release into the circulation and its characteristics: what is important for clinical applications BT - tumor liquid biopsies. In: Schaffner F, editor. Merlin J-L, von Bubnoff N, editors. Cham: Springer International Publishing; 2020. p. 163\u201380."},{"issue":"21","key":"1583_CR2","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-14-1190","volume":"21","author":"M Ignatiadis","year":"2015","unstructured":"Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res. 2015 Nov;21(21):4786\u2013800.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1583_CR3","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1158\/1078-0432.CCR-11-0400","volume":"17","author":"YJ Lee","year":"2011","unstructured":"Lee YJ, Yoon KA, Han JY, Kim HT, Yun T, Lee GK, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res. 2011;17(15):5179\u201387.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1583_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985\u201390.","journal-title":"Nat Med"},{"key":"1583_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00176","volume":"3","author":"ST Hennigan","year":"2019","unstructured":"Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, et al. Low abundance of circulating tumor DNA in localized prostate Cancer. JCO Precis Oncol. 2019;3:1\u201313.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"1583_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548\u201354.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"1583_CR7","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.21037\/jtd.2018.12.18","volume":"11","author":"G Herbreteau","year":"2019","unstructured":"Herbreteau G, Vall\u00e9e A, Charpentier S, Normanno N, Hofman P, Denis MG. Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. J Thorac Dis. 2019;11(Suppl 1):S113\u201326.","journal-title":"J Thorac Dis"},{"key":"1583_CR8","doi-asserted-by":"crossref","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science (80- ). 2018;359(6378):926\u2013930.","DOI":"10.1126\/science.aar3247"},{"issue":"December 2018","key":"1583_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2019.05.034","volume":"134","author":"B Zhang","year":"2019","unstructured":"Zhang B, Niu X, Zhang Q, Wang C, Liu B, Yue D, et al. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. Lung Cancer. 2019;134(December 2018):108\u201316.","journal-title":"Lung Cancer"},{"issue":"6","key":"1583_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/jnci\/djy156","volume":"111","author":"JK Sabari","year":"2019","unstructured":"Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, et al. A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers. J Natl Cancer Inst. 2019;111(6):575\u201383.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1583_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pros.23778","volume":"79","author":"MT Schweizer","year":"2019","unstructured":"Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, et al. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate. 2019;79(7):701\u20138.","journal-title":"Prostate."},{"issue":"6","key":"1583_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1183\/13993003.00676-2015","volume":"46","author":"C Tissot","year":"2015","unstructured":"Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015;46(6):1773\u201380.","journal-title":"Eur Respir J"},{"issue":"1","key":"1583_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07882-8","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv J, Chen Y, Zhou G, Qi Z, Tan KRL, Wang H, et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019;10(1):1\u201310.","journal-title":"Nat Commun"},{"issue":"4","key":"1583_CR14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1183\/09031936.00187909","volume":"36","author":"S Kumar","year":"2010","unstructured":"Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J. 2010;36(4):885\u201392.","journal-title":"Eur Respir J"},{"issue":"June","key":"1583_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2019.06.021","volume":"134","author":"PN Ding","year":"2019","unstructured":"Ding PN, Becker TM, Bray VJ, Chua W, Ma YF, Lynch D, et al. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a prospective study. Lung Cancer. 2019;134(June):187\u201393.","journal-title":"Lung Cancer"},{"issue":"10","key":"1583_CR16","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.jtho.2019.08.678","volume":"14","author":"S Ortiz-Cuaran","year":"2019","unstructured":"Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Jovelet C, et al. MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer. J Thorac Oncol. 2019;14(10):S337.","journal-title":"J Thorac Oncol"},{"issue":"16","key":"1583_CR17","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.3390\/ijms20163951","volume":"20","author":"M Del Re","year":"2019","unstructured":"Del Re M, Crucitta S, Gianfilippo G, Passaro A, Petrini I, Restante G, et al. Understanding the mechanisms of resistance in EGFR-positive NSCLC: from tissue to liquid biopsy to guide treatment strategy. Int J Mol Sci. 2019;20(16):3951.","journal-title":"Int J Mol Sci"},{"key":"1583_CR18","doi-asserted-by":"crossref","unstructured":"Tang C, Lee W-C, Reuben A, Chang L, Tran H, Little L, et al. Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial. Int J Radiat Oncol Biol Phys. 2019.","DOI":"10.1016\/j.ijrobp.2019.10.038"},{"key":"1583_CR19","unstructured":"National Lung Cancer Audit. National Lung Cancer Audit Report 2018. (for the audit period 2017). 2019."},{"issue":"27","key":"1583_CR20","doi-asserted-by":"publisher","first-page":"19368","DOI":"10.18632\/oncotarget.25053","volume":"9","author":"S Kageyama","year":"2018","unstructured":"Kageyama S, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, et al. Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. Oncotarget. 2018;9(27):19368\u201378.","journal-title":"Oncotarget."},{"issue":"6","key":"1583_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","volume":"25","author":"SF Leung","year":"2014","unstructured":"Leung SF, Chan KCA, Ma BB, Hui EP, Mo F, Chow KCK, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol. 2014;25(6):1204\u20138.","journal-title":"Ann Oncol"},{"issue":"24","key":"1583_CR22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461\u201370.","journal-title":"N Engl J Med"},{"issue":"823","key":"1583_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ijrobp.2011.05.061","volume":"1","author":"H Cao","year":"2012","unstructured":"Cao H, Banh A, Kwok S, Shi X, Wu S, Krakow TC, et al. Quantitation of the human papillomavirus DNA in the plasma of patients with Oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys Int J Radiat Oncol Biol Phys March. 2012;1(823):351\u20138.","journal-title":"Int J Radiat Oncol Biol Phys Int J Radiat Oncol Biol Phys March"},{"issue":"9","key":"1583_CR24","first-page":"2351","volume":"60","author":"YMD Lo","year":"2000","unstructured":"Lo YMD, Leung S-F, Chan LYS, Chan ATC, Lo K-W, Johnson PJ, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for. Cancer Res. 2000;60(9):2351\u20135.","journal-title":"Cancer Res"},{"issue":"3","key":"1583_CR25","first-page":"e676","volume":"102","author":"EL Chen","year":"2018","unstructured":"Chen EL, Chaudhuri AA, Nabet BY, Chabon JJ, Merriott DJ, Loo BW, et al. Analysis of circulating tumor DNA kinetics during stereotactic ablative radiation therapy for non-small cell lung Cancer. Int J Radiat Oncol. 2018;102(3):e676.","journal-title":"Int J Radiat Oncol."},{"issue":"2","key":"1583_CR26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijrobp.2017.06.021","volume":"99","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri AA, Lovejoy AF, Chabon JJ, Newman A, Stehr H, Merriott DJ, et al. Circulating tumor DNA analysis during radiation therapy for localized lung Cancer predicts treatment outcome. Int J Radiat Oncol. 2017;99(2):S1\u20132.","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"1583_CR27","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","volume":"155","author":"FC Detterbeck","year":"2018","unstructured":"Detterbeck FC. The eighth edition TNM stage classification for lung cancer: what does it mean on main street? J Thorac Cardiovasc Surg. 2018;155(1):356\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"1583_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.clon.2015.05.010","volume":"27","author":"KP Rooney","year":"2015","unstructured":"Rooney KP, McAleese J, Crockett C, Harney J, Eakin RL, Young VAL, et al. The impact of colleague peer review on the radiotherapy treatment planning process in the radical treatment of lung cancer. Clin Oncol (R Coll Radiol). 2015 Sep;27(9):514\u20138.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1583_CR29","doi-asserted-by":"crossref","unstructured":"Jiang J, Adams H, Yao L, Froehler S, Fang LT, Oster O, et al. Concordance of Genomic Alterations by Next Generation Sequencing ( NGS ) in Tumor Tissue vs . Cell-Free DNA in Stage I-IV NSCLC. J Mol Diagnostics. 2019;2.","DOI":"10.1016\/j.jmoldx.2019.10.013"},{"key":"1583_CR30","unstructured":"Roche Sequencing Solutions. AVENIO ctDNA Expanded Kit Product Specification [Internet]. Available from: https:\/\/sequencing.roche.com\/en\/products-solutions\/by-category\/assays\/ctdna-analysis-kits\/ctdna-expanded-kits\/specifications.html. Accessed 27 May 2020."},{"key":"1583_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5334\/ojb.47","volume":"5","author":"C Lewis","year":"2018","unstructured":"Lewis C, McQuaid S, Clark P, Murray P, McGuigan T, Greene C, et al. The Northern Ireland biobank: a Cancer focused repository of science. Open J Bioresour. 2018;5:1\u20136.","journal-title":"Open J Bioresour"},{"issue":"7","key":"1583_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","volume":"12","author":"S Jenkins","year":"2017","unstructured":"Jenkins S, Yang JCH, Ramalingam SS, Yu K, Patel S, Weston S, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non\u2013small cell lung Cancer. J Thorac Oncol. 2017;12(7):1061\u201370.","journal-title":"J Thorac Oncol"},{"key":"1583_CR33","doi-asserted-by":"crossref","unstructured":"Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, et al. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;(August):1\u201311.","DOI":"10.1093\/annonc\/mdz227"},{"issue":"5","key":"1583_CR34","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1016\/j.cllc.2018.04.022","volume":"19","author":"HH Loong","year":"2018","unstructured":"Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, et al. Clinical application of genomic profiling with circulating tumor DNA for Management of Advanced non\u2013Small-cell Lung Cancer in Asia. Clin Lung Cancer. 2018;19(5):e601\u20138.","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"1583_CR35","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394\u2013403.","journal-title":"Cancer Discov"},{"issue":"January","key":"1583_CR36","first-page":"1","volume":"6","author":"N Guo","year":"2016","unstructured":"Guo N, Lou F, Ma Y, Li J, Yang B, Chen W, et al. Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci Rep. 2016;6(January):1\u20138.","journal-title":"Sci Rep"},{"issue":"1","key":"1583_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jtho.2018.09.022","volume":"14","author":"YK Chae","year":"2019","unstructured":"Chae YK, Oh MS. Detection of minimal residual disease using ctDNA in lung Cancer: current evidence and future directions. J Thorac Oncol. 2019;14(1):16\u201324.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1583_CR38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/cam4.980","volume":"6","author":"W Hu","year":"2017","unstructured":"Hu W, Yang Y, Zhang L, Yin J, Huang J, Huang L, et al. Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. Cancer Med. 2017;6(5):962\u201374.","journal-title":"Cancer Med"},{"issue":"22","key":"1583_CR39","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-16-0613","volume":"22","author":"L Xi","year":"2016","unstructured":"Xi L, Pham THT, Payabyab EC, Sherry RM, Rosenberg SA, Raffeld M. Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. Clin Cancer Res. 2016;22(22):5480\u20136.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1583_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/mcs.a003772","volume":"5","author":"TM Butler","year":"2019","unstructured":"Butler TM, Boniface CT, Johnson-Camacho K, Tabatabaei S, Melendez D, Kelley T, et al. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer. Cold Spring Harb Mol case Stud. 2019;5(2):1\u201318.","journal-title":"Cold Spring Harb Mol case Stud"},{"key":"1583_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"K Kato","year":"2016","unstructured":"Kato K, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, et al. Transient appearance of circulating tumor DNA associated with de novo treatment. Sci Rep. 2016;6:1\u20138.","journal-title":"Sci Rep"},{"issue":"18","key":"1583_CR42","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.clinbiochem.2016.03.012","volume":"49","author":"Q Kang","year":"2016","unstructured":"Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, et al. Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem. 2016;49(18):1354\u201360.","journal-title":"Clin Biochem"},{"issue":"12","key":"1583_CR43","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928\u201337.","journal-title":"Nat Med"},{"issue":"7655","key":"1583_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 Apr 26;545(7655):446\u201351.","journal-title":"Nature."}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-020-01583-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:15:42Z","timestamp":1722964542000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01583-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01583-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients were prospectively consented to undergo serial venepuncture during the first week of radical radiotherapy alone, and for their clinical data to be used in conjunction with plasma analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No de-anonymised patient information contained within.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GH wishes to declare $2000.00 in speaker bureau fee from AstraZeneca (received August 2019) \u2013 donated directly to his institution. All other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}